Alto Neuroscience Valuation
| ANRO Stock | 16.89 0.45 2.74% |
At this time, the firm appears to be undervalued. Alto Neuroscience shows a prevailing Real Value of USD20.42 per share. The current price of the firm is USD16.89. Our model approximates the value of Alto Neuroscience from analyzing the firm fundamentals such as Shares Owned By Insiders of 6.43 %, current valuation of 414.42 M, and Return On Equity of -0.45 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Alto Neuroscience's valuation include:
Undervalued
Today
Please note that Alto Neuroscience's price fluctuation is not too volatile at this time. Calculation of the real value of Alto Neuroscience is based on 3 months time horizon. Increasing Alto Neuroscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alto Neuroscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alto Stock. However, Alto Neuroscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.89 | Real 20.42 | Target 31.13 | Hype 17.32 |
The intrinsic value of Alto Neuroscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alto Neuroscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alto Neuroscience helps investors to forecast how Alto stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alto Neuroscience more accurately as focusing exclusively on Alto Neuroscience's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Alto Neuroscience's intrinsic value based on its ongoing forecasts of Alto Neuroscience's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Alto Neuroscience's closest peers.
Alto Neuroscience Cash |
|
Alto Neuroscience Total Value Analysis
Alto Neuroscience is presently projected to have valuation of 414.42 M with market capitalization of 524.71 M, debt of 16.94 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Alto Neuroscience fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
414.42 M | 524.71 M | 16.94 M |
Alto Neuroscience Asset Utilization
One of the ways to look at asset utilization of Alto is to check how much profit was generated for every dollar of assets it reports. Alto Neuroscience shows a negative utilization of assets of -0.24 percent, losing USD0.002448 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Alto Neuroscience shows how discouraging it operates for each dollar spent on its assets.Alto Neuroscience Profitability Analysis
Based on the measurements of profitability obtained from Alto Neuroscience's financial statements, Alto Neuroscience may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Alto Neuroscience's ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -55.3 M | Current Value -52.5 M | Quarterly Volatility 21.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.25 | 0.28 |
|
|
For Alto Neuroscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alto Neuroscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alto Neuroscience utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alto Neuroscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alto Neuroscience over time as well as its relative position and ranking within its peers.
Alto Neuroscience Earnings per Share Projection vs Actual
The next projected EPS of Alto Neuroscience is estimated to be -0.485 with future projections ranging from a low of -0.56 to a high of -0.41. Alto Neuroscience's most recent 12-month trailing earnings per share (EPS TTM) is at -2.3. Please be aware that the consensus of earnings estimates for Alto Neuroscience is based on EPS before non-recurring items and includes expenses related to employee stock options.Alto Neuroscience Earnings Estimation Breakdown
The calculation of Alto Neuroscience's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Alto Neuroscience is estimated to be -0.485 with the future projection ranging from a low of -0.56 to a high of -0.41. Please be aware that this consensus of annual earnings estimates for Alto Neuroscience is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.56 Lowest | Expected EPS | -0.41 Highest |
Alto Neuroscience Earnings Projection Consensus
Suppose the current estimates of Alto Neuroscience's value are higher than the current market price of the Alto Neuroscience stock. In this case, investors may conclude that Alto Neuroscience is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Alto Neuroscience's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 10 | 73.72% | 0.0 | -0.485 | -2.3 |
Alto Neuroscience Ownership Allocation
Alto Neuroscience holds a total of 31.07 Million outstanding shares. The majority of Alto Neuroscience outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alto Neuroscience to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alto Neuroscience. Please pay attention to any change in the institutional holdings of Alto Neuroscience as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Alto Neuroscience Profitability Analysis
Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0.About Alto Neuroscience Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Alto Neuroscience. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Alto Neuroscience based exclusively on its fundamental and basic technical indicators. By analyzing Alto Neuroscience's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Alto Neuroscience's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Alto Neuroscience. We calculate exposure to Alto Neuroscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Alto Neuroscience's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -451.8 K | -474.4 K | |
| Pretax Profit Margin | (39.37) | (41.34) | |
| Operating Profit Margin | (51.67) | (54.25) | |
| Net Loss | (39.37) | (41.34) | |
| Gross Profit Margin | 0.28 | 0.25 |
Alto Neuroscience Current Valuation Indicators
Alto Neuroscience's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Alto Neuroscience's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Alto Neuroscience, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Alto Neuroscience's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Alto Neuroscience's worth.When determining whether Alto Neuroscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alto Neuroscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alto Neuroscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alto Neuroscience Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.